SCHEMBL722505

SCHEMBL722505

Cn1cc(-c2ccc(-c3cc4nccc(-c5cncnc5)c4o3)cc2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 7/20 0.42
CDK8 P49336 7/20 0.42
TTK P33981 1/20 0.41
ALK Q9UM73 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
ACVR1 Q04771 1/20 0.37
AURKB Q96GD4 3/20 0.37
MAP3K7 O43318 1/20 0.37
KDR P35968 1/20 0.37
TAB1 Q15750 1/20 0.37
AURKA O14965 2/20 0.37
INCENP Q9NQS7 2/20 0.37
TPX2 Q9ULW0 2/20 0.37
DYRK1A Q13627 1/20 0.36
LRRK2 Q5S007 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PI4KA P42356 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723758 0.89 DYRK1A (0.47) CCNCCDK8ALKMKNK1MKNK2
SCHEMBL10268949 0.85 AURKB (0.46) CCNCCDK8ALKAURKBMAP3K7
SCHEMBL15209645 0.85 CCNC (0.39) CCNCCDK8ALKMKNK1MKNK2
SCHEMBL723385 0.84 MTOR (0.43) CCNCCDK8ALKMKNK1MKNK2
SCHEMBL15216719 0.84 CCNC (0.41) CCNCCDK8ALKMKNK1MKNK2
SCHEMBL722231 0.84 MAP4K4 (0.42) CCNCCDK8PIK3CAMET
SCHEMBL725211 0.84 CCNC (0.40) CCNCCDK8MKNK1MKNK2MAP3K7
SCHEMBL723453 0.84 CCNC (0.40) CCNCCDK8ALKMKNK1MKNK2
SCHEMBL721690 0.83 AURKB (0.38) CCNCCDK8TTKALKACVR1
SCHEMBL15209552 0.83 FGFR1 (0.41) CCNCCDK8TTKPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB CCNC 2402/4885CDK8 2061/4885TTK 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.